Using individualized predictive disease modeling to identify patients with the potential to benefit from a disease management program for diabetes mellitus

Disease Management

Volumn 9, Issue 4, 2006, Pages 242-256

  Weber, Christian ^a   Neeser, Kurt ^a  

^a Institute for Medical Informatics and Biostatistics   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ADULT; ARTICLE; CALCULATION; CLINICAL ASSESSMENT; COHORT ANALYSIS; COST CONTROL; DIABETES MELLITUS; DISEASE MANAGEMENT PROGRAM; DISEASE MODEL; EVALUATION; FEMALE; HEALTH PROGRAM; HUMAN; HYPOTHESIS; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT IDENTIFICATION; PATIENT SELECTION; PREDICTION; RISK FACTOR;

COSTS AND COST ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FEMALE; GERMANY; HUMANS; MALE; MARKOV CHAINS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; STATISTICS, NONPARAMETRIC;

EID: 33750955505     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.2006.9.242     Document Type: Article

References (67)

1. International Diabetes Federation. Diabetes atlas, 2nd ed. Paris: IDF, 2003.
2. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828.
3. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:136-145.
4. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990;13:1-11.
5. Fuller JH, McCartney P, Jarrett RJ, et al. Hyperglycaemia and coronary heart disease: the Whitehall study. J Chronic Dis 1979;32:721-728.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
7. Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-1720.
8. Hogan P, Dall T, Nikolov P, American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-932.
9. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Gortz A. [Costs of type 2 diabetes in Germany. Results of the CODE-2 study]. Dtsch Med Wochenschr 2001;126:585-589.
10. Norris SL, Nichols PJ, Caspersen CJ, et al. The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prev Med 2002;22:15-38.
11. Renders CM, Valk GD, Griffin S, Wagner EH, Eijk JT, Assendelft WJ. Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. Cochrane Database Syst Rev 2001;CD001481.
12. Sidorov J, Shull R, Tomcavage J, Girolami S, Lawton N, Harris R. Does diabetes disease management save money and improve outcomes? A report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease management program among patients fulfilling health employer data and information set criteria. Diabetes Care 2002;25:684-689.
13. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. BMJ 2002;325:925.
14. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-modeling studies. Value Health 2003;6:9-17.
15. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001;4:348-361.
16. Institute for Medical Informatics and Biostatistics. Available at: www.imib.ch. Accessed September 25, 2005.
17. Häussler B, Berger U. Bedingungen für effektive Disease-Management-Programme. Analyse, Bewertung und Lösungsansätze für Qualität und Finanzierung. Berlin: IGES, 2005.
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
19. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994;11:223-241.
20. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999;16:179-192.
21. Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999;16:586-590.
22. Borch-Johnsen K, Andersen P, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985;28:590-596.
23. Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia 1978;14:75-87.
24. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-266.
25. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989;4:859-863.
26. Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med 1989;111:788-796.
27. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-988.
28. Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 1996;45:1289-1298.
29. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med 1985;78:785-794.
30. Nelson RG, Knowler WC, McCance DR, et al. Determinants of end-stage renal disease in pima indians with type 2 (non-insulin-dependent) diabetes mellitus and proteinuria. Diabetologia 1993;36:1087-1093.
31. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. the collaborative study group. [Erratum in N Engl J Med 1993 13;330:152.] N Engl J Med 1993;329:1456-1462.
32. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. the diabetes control and complications trial research group. N Engl J Med 1993;329:977-986.
33. Miles AM, Friedman EA. Dialytic therapy for diabetic patients with terminal renal failure. Curr Opin Nephrol Hypertens 1993;2:868-875.
34. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-279.
35. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin-dependent diabetic patients: an economic evaluation. BMJ 1995;311:1595-1599.
36. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003;348:2285-2293.
37. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001;134:370-379.
38. McIntosh A, Hutchinson A, Marshall S, et al. Clinical guidelines and evidence review for type 2 diabetes. Renal disease: prevention and early management. Sheffield, UK: ScHARR, University of Sheffield, 2002.
39. Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004;328:1105-1109.
40. Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996;39:587-593.
41. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-298.
42. Jensen-Urstad KJ, Reichard PG, Rosfors JS, Lindblad LE, Jensen-Urstad MT. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes 1996;45:1253-1258.
43. Karlson B, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabetic Med 1993;10:449-454.
44. Donahue RP, Goldberg RJ, Chen Z, Gore JM, Alpert JS. The influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective. J Clin Epidemiol 1993;46:245-252.
45. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993;22:1788-1794.
46. Herlitz J, Bang A, Karlson BW. Mortality, place and mode of death and reinfarction during a period of 5 years after acute myocardial infarction in diabetic and non-diabetic patients. Cardiology 1996;87:423-428.
47. Kornowski R, Goldbourt U, Zion M, et al. Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction. SPRINT Study Group. Am J Cardiol 1993;72:883-888.
48. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 2000;102:1014-1019.
49. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-318.
50. Kittner SJ, White LR, Losonczy KG, Wolf PA, Hebel JR. Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. JAMA 1990;264:1267-1270.
51. Davis TM, Millns H, Stratton IM, Holman RR, Turner RC. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 1999;159:1097-1103.
52. Sprafka JM, Burke GL, Folsom AR, McGovern PG, Hahn LP. Trends in diabetes prevalence among stroke patients and effect of diabetes on survival. The Minnesota Heart Survey. Diabetic Med 1994;11:678-684.
53. Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke. The Framingham Study. Stroke 1982;13:290-295.
54. Olsson T, Viitanen M, Asplund K, Eriksson S, Hagg E. Prognosis after stroke in diabetic patients. A controlled prospective study. Diabetologia 1990;33:244-249.
55. von Arbin M, Britton M, de Faire U. Mortality and recurrences during eight years following stroke. J Intern Med 1992;231:43-48.
56. Klein R, Klein BE, Moss SE, Davis MD, De Mets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-2871.
57. nd ed. 1995. Washington, DC: NIH.
58. Klein R, Klein B, Moss SE. The Wisconsin Epidemiology study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989;107:237-243.
59. Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology. Ophthalmology 1991;98:1565-1573.
60. Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA. Lower-extremity amputation in people with diabetes. Epidemiology and prevention. Diabetes Care 1989;12:24-31.
61. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 1983;6:87-91.
62. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-616.
63. McNeely MJ, Boyko EJ, Ahroni JH, et al. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care 1995;18:216-219.
64. Fylling CP, Knighton DR. Amputation in the diabetic population: incidence, causes, cost, treatment, and prevention. J Enterostomal Ther 1989;16:247-255.
65. Schifter DE, Ajzen I. Intention, perceived control, and weight loss: an application of the theory of planned behavior. J Pers Soc Psychol 1985;49:843-851.
66. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 1977;84:191-215.
67. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot 1997;12:38-48.